Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 218 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... April 12, 2024 Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer May 7, 2021 This Bar of Soap with a Lump Will Help You Remember... May 31, 2019 Satisfying Snacks November 13, 2020 Load more HOT NEWS Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer Courageous children receive Star Awards in virtual celebration
